- Article
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration
- Sama F. Sleiman,
- Jill Berlin,
- Manuela Basso,
- Saravanan S.Karuppagounder,
- Jürgen Rohr and
- Rajiv R. Ratan
Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1...

